Compare Novo Nordisk A/S (NVO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs GeneDx Holdings Corp — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Novo Nordisk A/S is far larger — about 122.5× GeneDx Holdings Corp's market cap, and Novo Nordisk A/S pays a 3.63% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| NVO | WGS | |
|---|---|---|
Market Cap | $220.53B | $1.80B |
Sector | Health | Technology |
52-Week High | $71.70 | $167.51 |
52-Week Low | $35.29 | $34.51 |
Enterprise Value | $239.49B | $1.80B |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
